SCHEMBL2366844

SCHEMBL2366844

COCCOCC1COC(=O)N1c1ccc(C(=O)N2CCN(c3ncc(C4CC4)cc3C)CC2)cc1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
EGLN1 Q9GZT9 3/20 0.36
NTSR1 P30989 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
FASN P49327 4/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
USP2 O75604 1/20 0.33
SSTR5 P35346 1/20 0.33
MGLL Q99685 1/20 0.33
PIK3CA P42336 1/20 0.33
SLC6A7 Q99884 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366837 1.00 LMNA (0.36) LMNAEGLN1NTSR1MEN1KMT2A
SCHEMBL7942647 0.93 LMNA (0.35) LMNAEGLN1NTSR1MEN1KMT2A
SCHEMBL2366652 0.93 LMNA (0.39) LMNAEGLN1NTSR1MEN1KMT2A
SCHEMBL2366647 0.93 LMNA (0.39) LMNAEGLN1NTSR1MEN1KMT2A
SCHEMBL2366014 0.93 EGLN1 (0.36) LMNAEGLN1NTSR1MEN1KMT2A
SCHEMBL2366005 0.93 EGLN1 (0.36) LMNAEGLN1NTSR1MEN1KMT2A
SCHEMBL2366914 0.88 EGLN1 (0.38) LMNAEGLN1NTSR1MEN1KMT2A
SCHEMBL2366911 0.88 EGLN1 (0.38) LMNAEGLN1NTSR1MEN1KMT2A
SCHEMBL2365683 0.88 P2RX3 (0.38) LMNAEGLN1MEN1KMT2AALDH1A1
SCHEMBL2365671 0.88 P2RX3 (0.38) LMNAEGLN1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 LMNA 3668/4885EGLN1 128/4885NTSR1 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.